Back to Search Start Over

A long interval between priming and boosting SARS-CoV-2 mRNA vaccine doses enhances B cell responses with limited impact on T cell immunity

Authors :
Alexandre Nicolas
Gérémy Sannier
Mathieu Dubé
Manon Nayrac
Mark M. Painter
Rishi R. Goel
Mélanie Laporte
Halima Medjahed
Justine C. Williams
Nathalie Brassard
Julia Niessl
Laurie Gokool
Chantal Morrisseau
Pascale Arlotto
Cécile Tremblay
Valérie Martel-Laferrière
Andrés Finzi
Allison R. Greenplate
E. John Wherry
Daniel E. Kaufmann
Publication Year :
2022
Publisher :
Cold Spring Harbor Laboratory, 2022.

Abstract

SUMMARYSpacing the first two doses of SARS-CoV-2 mRNA vaccines beyond 3-4 weeks raised initial concerns about vaccine efficacy. While studies have since shown that long-interval regimens induce robust antibody responses, their impact on B and T cell immunity is poorly known. Here, we compare in SARS-CoV-2 naïve donors B and T cell responses to two mRNA vaccine doses administered 3-4 versus 16 weeks apart. After boost, the longer interval results in higher magnitude and a more mature phenotype of RBD-specific B cells. While the two geographically distinct cohorts present quantitative and qualitative differences in T cell responses at baseline and after priming, the second dose led to convergent features with overall similar magnitude, phenotype and function of CD4+ and CD8+ T cell responses at post-boost memory timepoints. Therefore, compared to standard regimens, a 16-week interval has a favorable impact on the B cell compartment but minimally affects T cell immunity.

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....24f43ad386718a907b6def47c102af1f
Full Text :
https://doi.org/10.1101/2022.08.03.502672